The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development

References

• World Health Organization. Rolling updates on coronavirus disease (COVID-19). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.
   PubMed Web of Science ®Google Scholar
• Finkel Y, Mizrahi O, Nachshon A, et al. The coding capacity of SARS-CoV-2. Nature. 2021;589:125–130.
   PubMed Web of Science ®Google Scholar
• Kang S, Yang M, Hong Z, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 2020;10:1228–1238.
   PubMed Web of Science ®Google Scholar
• Peng Y, Du N, Lei Y, et al. Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. EMBO J. 2020;39:e105938.
   PubMed Web of Science ®Google Scholar
• Jia Z, Liu C, Chen Y, et al. Crystal structure of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies. FEBS J. 2022;289:3813–3825.
   PubMed Web of Science ®Google Scholar
• Iserman C, Roden CA, Boerneke MA, et al. Genomic RNA elements drive phase separation of the SARS-CoV-2 nucleocapsid. Mol Cell. 2020;80:1078–1091.e6.
   PubMed Web of Science ®Google Scholar
• Perdikari TM, Murthy AC, Ryan VH, et al. SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs. EMBO J. 2020;39:e106478.
   PubMed Web of Science ®Google Scholar
• Biswal M, Lu J, Song J. SARS-CoV-2 nucleocapsid protein targets a conserved surface groove of the NTF2-like domain of G3BP1. J Mol Biol. 2022;434:167516.
   PubMed Web of Science ®Google Scholar
• Somasekharan SP, Gleave M. SARS-CoV-2 nucleocapsid protein interacts with immunoregulators and stress granules and phase separates to form liquid droplets. FEBS Lett. 2021;595:2872–2896.
   PubMed Web of Science ®Google Scholar
• Li Y, Lu S, Gu J, et al. SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation. Protein Cell. 2022;13:602–614.
   PubMed Web of Science ®Google Scholar
• Toldo S, Bussani R, Nuzzi V, et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res. 2021;70:7–10.
   PubMed Web of Science ®Google Scholar
• Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218:e20201707.
   PubMed Web of Science ®Google Scholar
• Pan P, Shen M, Yu Z, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun. 2021;12:4664.
   PubMed Web of Science ®Google Scholar
• Wu Y, Ma L, Cai S, et al. RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation. Signal Transduct Target Ther. 2021;6:167.
   PubMed Web of Science ®Google Scholar
• Chen L, Guan W, Qiu ZE, et al. SARS-CoV-2 nucleocapsid protein triggers hyperinflammation via protein-protein interaction-mediated intracellular Cl− accumulation in respiratory epithelium. Signal Transduct Target Ther. 2022;7:255.
   PubMed Web of Science ®Google Scholar
• Zhao X, Nicholls JM, Chen YG. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Samd3 and modulates transforming growth factor-beta signaling. J Biol Chem. 2008;283:3272–3280.
   PubMed Web of Science ®Google Scholar
• Olea B, Albert E, Torres I, et al. SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: frequency and association with inflammatory and tissue-damage biomarkers. J Med Virol. 2022;94:222–228.
   PubMed Web of Science ®Google Scholar
• Yokoyama R, Kurano M, Nakano Y, et al. Association of the serum levels of the nucleocapsid antigen of SARS-CoV-2 with the diagnosis, disease severity, and antibody titers in patients with COVID-19: a retrospective cross-sectional study. Front Microbiol. 2021;12:791489.
   PubMed Web of Science ®Google Scholar
• Favresse J, Bayart JL, David C, et al. Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity. J Infect. 2022;84:e4–e6.
   PubMed Web of Science ®Google Scholar
• Gao T, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022;7:318.
   PubMed Web of Science ®Google Scholar
• Ali YM, Ferrari M, Lynch NJ, et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol. 2021;12:714511.
   PubMed Web of Science ®Google Scholar
• Qian Y, Lei T, Patel PS, et al. Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by simvastatin. J Virol. 2021;95:e0139621.
   PubMed Web of Science ®Google Scholar
• Xia J, Tang W, Wang J, et al. SARS-CoV-2 N protein induces acute lung injury in mice via NF-κB activation. Front Immunol. 2021;12:791753.
   PubMed Web of Science ®Google Scholar
• Nakayama EE, Kubota-Koketsu R, Sasaki T, et al. Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein. Sci Rep. 2022;12:8108.
   PubMed Web of Science ®Google Scholar
• Freda CT, Yin W, Ghebrehiwet B, et al. SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts. Clin Immunol. 2021;227:108733.
   PubMed Web of Science ®Google Scholar
• Kao MS, Yang JH, Balasubramaniam A, et al. Colonization in nasal cavities by staphylococcus epidermidis mitigates SARS-CoV-2 nucleocapsid phosphoprotein-induced interleukin (IL)-6 in the lung. Microb Biotechnol. 2022;15:1984–1994.
   PubMed Web of Science ®Google Scholar
• Savellini GG, Anichini G, Gandolfo C, et al. SARS-CoV-2 N protein targets TRIM25-mediated RIG-I activation to suppress innate immunity. Viruses. 2021;13:1439.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sui L, Wu P, et al. A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response. Signal Transduct Target Ther. 2021;6:331.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Shin OS. SARS-CoV-2 nucleocapsid protein targets RIG-I-like receptor pathways to inhibit the induction of interferon response. Cells. 2021;10:530.
   PubMed Web of Science ®Google Scholar
• Zheng ZQ, Wang SY, Xu ZS, et al. SARS-CoV-2 nucleocapsid protein impairs stress granule formation to promote viral replication. Cell Discov. 2021;7:38.
   PubMed Web of Science ®Google Scholar
• Cui L, Wang H, Ji Y, et al. The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells. J Virol. 2015;89:9029–9043.
   PubMed Web of Science ®Google Scholar
• Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, et al. Severe acute respiratory syndrome coronavirus open Reading frame (ORF) 3b, ORF6, and nucleocapsid proteins functions as interferon antagonists. J Virol. 2007;81:548–557.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen J, Hu D, et al. SARS-CoV-2 N protein induces acute kidney injury via Smad3-dependent G1 cell cycle arrest mechanism. Adv Sci. 2022;9:2103248.
   Web of Science ®Google Scholar
• Ma J, Zhu F, Zhao M, et al. SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage. EMBO J. 2021;40:e108249.
   PubMed Web of Science ®Google Scholar
• Ren Y, Wang A, Fang Y, et al. SARS-CoV-2 membrane glycoprotein M triggers apoptosis with the assistance of nucleocapsid protein N in cells. Front Cell Infect Microbiol. 2021;11:706252.
   PubMed Web of Science ®Google Scholar
• Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, et al. Interaction between SARS-CoV-2 N-protein and α-synuclein accelerate amyloid formation. ACS Chem Neurosci. 2022;13:143–150.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Deng J, Han L, et al. SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules. Signal Transduct Target Ther. 2022;7:22.
   PubMed Web of Science ®Google Scholar
• Wang S, Dai T, Qin Z, et al. Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat Cell Biol. 2021;23:718–732.
   PubMed Web of Science ®Google Scholar
• Mu J, Fang Y, Yang Q, et al. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 2020;6:65.
   PubMed Web of Science ®Google Scholar
• Mu J, Xu J, Zhang L, et al. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells. Sci China Life Sci. 2020;63:1413–1416.
   PubMed Web of Science ®Google Scholar
• Chen YM, Wei JL, Qin RS, et al. Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein. Pharm Biol. 2022;60:862–878.
   PubMed Web of Science ®Google Scholar
• Kim SS, Sze L, Liu C, et al. The stress granule protein G3BP1 binds viral dsRNA and RIG-I to enhance interferon-beta response. J Biol Chem. 2019;294:6430–6438.
   PubMed Web of Science ®Google Scholar
• Xia H, Cao Z, Xie X, et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 2020;33:108234.
   PubMed Web of Science ®Google Scholar
• Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810.
   PubMed Web of Science ®Google Scholar
• Li JY, Liao CH, Wang Q, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074.
   PubMed Web of Science ®Google Scholar
• Chen K, Xiao F, Hu D, et al. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-β production. Viruses. 2021;13:47.
   Web of Science ®Google Scholar
• Stravalaci M, Pagani I, Paraboschi EM, et al. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nat Immunol. 2022;23:275–286.
   PubMed Web of Science ®Google Scholar
• Nelson RW, Chen Y, Venezia OL, et al. SARS-CoV-2 epitope-specific CD4+ memory T cell responses across COVID-19 disease severity and antibody durability. Sci Immunol. 2022;7:eabl9464.
   PubMed Web of Science ®Google Scholar
• Martner A, Wiktorin HG, Törnell A, et al. Transient and durable T cell reactivity after COVID-19. Proc Natl Acad Sci U S A. 2022;119:e2203659119.
   PubMed Web of Science ®Google Scholar
• Koerber N, Priller A, Yazici S, et al. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13:153.
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36:109518.
   PubMed Web of Science ®Google Scholar
• Visvabharathy L, Hanson B, Orban Z, et al. Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and response to vaccination. MedRxiv. 2021;2021.08.08.21261763.
   Google Scholar
• Yang L, Xu Q, Yang B, et al. Igg antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients. BMC Microbiol. 2021;21:351.
   PubMed Web of Science ®Google Scholar
• Feng W, Xiang Y, Wu L, et al. Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine. J Clin Lab Anal. 2022;36:e24479.
   PubMed Web of Science ®Google Scholar
• Sen AR, Sanders EC, Gabriel KN, et al. Predicting COVID-19 severity with a specific nucleocapsid antibody plus disease risk factor score. mSphere. 2021;6:e00203–21.
   PubMed Web of Science ®Google Scholar
• Voss C, Esmail S, Liu X, et al. Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. JCI Insight. 2021;6:e148855.
   PubMed Web of Science ®Google Scholar
• Lyudovyk O, Kim JY, Qualls D, et al. Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell. 2022;40:738–753.e5.
   PubMed Web of Science ®Google Scholar
• López-Muñoz AD, Kosik I, Holly J, et al. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci Adv. 2022;8:eabp9770.
   PubMed Web of Science ®Google Scholar
• Hartley GE, Edwars ESJ, Aui PM, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5:eabf8891.
   PubMed Web of Science ®Google Scholar
• Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12:62–73.
   PubMed Web of Science ®Google Scholar
• Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21:1336–1345.
   PubMed Web of Science ®Google Scholar
• Bange EM, Han NA, Wileyto P, et al. CD8(+) t cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280–1289.
   PubMed Web of Science ®Google Scholar
• Peng Y, Felce SL, Dong D, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat Immunol. 2022;23:50–61.
   PubMed Web of Science ®Google Scholar
• Lineburg KE, Grant EJ, Swaminathan S, et al. CD8+ t cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity. 2021;54:1055–1065.e5.
   PubMed Web of Science ®Google Scholar
• Nguyen THO, Rowntree LC, Petersen J, et al. CD8+ t cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naïve precursors frequency and TCR promiscuity. Immunity. 2021;54:1066–1082.e5.
   PubMed Web of Science ®Google Scholar
• He J, Huang J, Zhang Y, et al. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice. J Med Virol. 2021;93:1923–1925.
   PubMed Web of Science ®Google Scholar
• Chiuppesi F, Nguyen VH, Park Y, et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. NPJ Vaccines. 2022;7:7.
   PubMed Web of Science ®Google Scholar
• Wussow F, Kha M, Faircloth K, et al. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. iScience. 2022;25:104457.
   PubMed Web of Science ®Google Scholar
• Chiuppesi F, Zaia JA, Frankel PH, et al. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe. 2022;3:e252–e264.
   PubMedGoogle Scholar
• Chiuppesi F, Zaia JA, Frankel PH, et al. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. iScience. 2022;25:104745.
   PubMed Web of Science ®Google Scholar
• Jia Q, Bielefeldt-Ohmann H, Maison RM, et al. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 membrane and nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. NPJ Vaccines. 2021;6:47.
   PubMed Web of Science ®Google Scholar
• Matchett WE, Joag V, Stolley JM, et al. Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J Immunol. 2021;207:376–379.
   PubMed Web of Science ®Google Scholar
• Ahn JY, Lee J, Suh YS, et al. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe. 2022;3:e173–e183.
   PubMedGoogle Scholar
• Castro JT, Azevedo P, Fumagalli MJ, et al. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-nucleocapsid fusion protein. Nat Commun. 2022;13:4831.
   PubMed Web of Science ®Google Scholar
• Afkhami S, D’Agostino MR, Zhang A, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896–915.e19.
   PubMed Web of Science ®Google Scholar
• Dangi T, Class J, Palacio N, et al. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep. 2021;36:109664.
   PubMed Web of Science ®Google Scholar
• Jiang W, Shi L, Cai L, et al. A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. Cell Rep. 2021;37:110112.
   PubMed Web of Science ®Google Scholar
• Wang CY, Hwang KP, Kuo HK, et al. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022;132:e157707.
   PubMed Web of Science ®Google Scholar
• Hajnik RL, Plante JA, Liang Y, et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci Transl Med. 2022;14:eabq1945.
   PubMed Web of Science ®Google Scholar